A recombinant bispecific single-chain Fv antibody against HLA class II and FcγRIII (CD16) triggers effective lysis of lymphoma cells

Joerg Bruenke, Barbara Fischer, Karin Barbin, Katja Schreiter, Yvonne Wachter, Kerstin Mahr, Fritz Titgemeyer, Michael Niederweis, Matthias Peipp, Susan J. Zunino, Roland Repp, Thomas Valerius, Georg H. Fey

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Bispecific antibodies offer the possibility of improving effector-cell recruitment for antibody therapy. For this purpose, a recombinant bispecific single-chain Fv antibody (bsscFv), directed against FcγRIII (CD16) and human leucocyte antigen (HLA) class II, was constructed and tested in functional assays. RNA from the hybridomas 3G8 and F3.3, reacting with CD16 and HLA class II, respectively, was used to generate phage display libraries. From these libraries, reactive phages were isolated and the bsscFv was constructed by connecting both single-chain Fv components through a 20 amino acid flexible linker. After expression in SF21 insect cells and chromatographic purification, the bsscFv bound specifically and simultaneously to both antigens. The affinities of the anti-CD16 and the anti-HLA class II scFv components of the bsscFv were 8.6 × 10-8 mol/l and 13.7 × 10-8 mol/l, respectively, which was approximately sevenfold lower than the F(ab) fragments of the parental antibodies. In antibody-dependent cellular cytotoxicity experiments with human mononuclear cells as effectors, the bsscFv-mediated specific lysis of both HLA class II-positive, malignant human B-lymphoid cell lines and primary cells from patients with chronic B-cell lymphocytic leukaemia. Optimal lysis was obtained at bsscFv concentrations of approximately 400 ng/ml, similar to the concentration required for maximum lysis by the corresponding chemically linked bispecific antibody. Thus, this recombinant bsscFv-antibody is an efficient molecule for effector-cell mediated lysis of malignant human B-lymphoid cells.

Original languageEnglish (US)
Pages (from-to)167-179
Number of pages13
JournalBritish Journal of Haematology
Volume125
Issue number2
DOIs
StatePublished - Apr 2004
Externally publishedYes

Fingerprint

Bispecific Antibodies
Single-Chain Antibodies
HLA Antigens
Lymphoma
Bacteriophages
Libraries
Antibodies
Lymphocytes
Sf9 Cells
Immunoglobulin Fragments
Hybridomas
B-Cell Chronic Lymphocytic Leukemia
Insects
RNA
Antigens
Amino Acids
Cell Line

Keywords

  • Antibodies
  • Fc receptors
  • Major histocompatibility complex
  • Natural killer cells
  • Tumour immunity

ASJC Scopus subject areas

  • Hematology

Cite this

A recombinant bispecific single-chain Fv antibody against HLA class II and FcγRIII (CD16) triggers effective lysis of lymphoma cells. / Bruenke, Joerg; Fischer, Barbara; Barbin, Karin; Schreiter, Katja; Wachter, Yvonne; Mahr, Kerstin; Titgemeyer, Fritz; Niederweis, Michael; Peipp, Matthias; Zunino, Susan J.; Repp, Roland; Valerius, Thomas; Fey, Georg H.

In: British Journal of Haematology, Vol. 125, No. 2, 04.2004, p. 167-179.

Research output: Contribution to journalArticle

Bruenke, J, Fischer, B, Barbin, K, Schreiter, K, Wachter, Y, Mahr, K, Titgemeyer, F, Niederweis, M, Peipp, M, Zunino, SJ, Repp, R, Valerius, T & Fey, GH 2004, 'A recombinant bispecific single-chain Fv antibody against HLA class II and FcγRIII (CD16) triggers effective lysis of lymphoma cells', British Journal of Haematology, vol. 125, no. 2, pp. 167-179. https://doi.org/10.1111/j.1365-2141.2004.04893.x
Bruenke, Joerg ; Fischer, Barbara ; Barbin, Karin ; Schreiter, Katja ; Wachter, Yvonne ; Mahr, Kerstin ; Titgemeyer, Fritz ; Niederweis, Michael ; Peipp, Matthias ; Zunino, Susan J. ; Repp, Roland ; Valerius, Thomas ; Fey, Georg H. / A recombinant bispecific single-chain Fv antibody against HLA class II and FcγRIII (CD16) triggers effective lysis of lymphoma cells. In: British Journal of Haematology. 2004 ; Vol. 125, No. 2. pp. 167-179.
@article{7027eb25fc3a4507bf33370e25f3cec4,
title = "A recombinant bispecific single-chain Fv antibody against HLA class II and FcγRIII (CD16) triggers effective lysis of lymphoma cells",
abstract = "Bispecific antibodies offer the possibility of improving effector-cell recruitment for antibody therapy. For this purpose, a recombinant bispecific single-chain Fv antibody (bsscFv), directed against FcγRIII (CD16) and human leucocyte antigen (HLA) class II, was constructed and tested in functional assays. RNA from the hybridomas 3G8 and F3.3, reacting with CD16 and HLA class II, respectively, was used to generate phage display libraries. From these libraries, reactive phages were isolated and the bsscFv was constructed by connecting both single-chain Fv components through a 20 amino acid flexible linker. After expression in SF21 insect cells and chromatographic purification, the bsscFv bound specifically and simultaneously to both antigens. The affinities of the anti-CD16 and the anti-HLA class II scFv components of the bsscFv were 8.6 × 10-8 mol/l and 13.7 × 10-8 mol/l, respectively, which was approximately sevenfold lower than the F(ab) fragments of the parental antibodies. In antibody-dependent cellular cytotoxicity experiments with human mononuclear cells as effectors, the bsscFv-mediated specific lysis of both HLA class II-positive, malignant human B-lymphoid cell lines and primary cells from patients with chronic B-cell lymphocytic leukaemia. Optimal lysis was obtained at bsscFv concentrations of approximately 400 ng/ml, similar to the concentration required for maximum lysis by the corresponding chemically linked bispecific antibody. Thus, this recombinant bsscFv-antibody is an efficient molecule for effector-cell mediated lysis of malignant human B-lymphoid cells.",
keywords = "Antibodies, Fc receptors, Major histocompatibility complex, Natural killer cells, Tumour immunity",
author = "Joerg Bruenke and Barbara Fischer and Karin Barbin and Katja Schreiter and Yvonne Wachter and Kerstin Mahr and Fritz Titgemeyer and Michael Niederweis and Matthias Peipp and Zunino, {Susan J.} and Roland Repp and Thomas Valerius and Fey, {Georg H.}",
year = "2004",
month = "4",
doi = "10.1111/j.1365-2141.2004.04893.x",
language = "English (US)",
volume = "125",
pages = "167--179",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - A recombinant bispecific single-chain Fv antibody against HLA class II and FcγRIII (CD16) triggers effective lysis of lymphoma cells

AU - Bruenke, Joerg

AU - Fischer, Barbara

AU - Barbin, Karin

AU - Schreiter, Katja

AU - Wachter, Yvonne

AU - Mahr, Kerstin

AU - Titgemeyer, Fritz

AU - Niederweis, Michael

AU - Peipp, Matthias

AU - Zunino, Susan J.

AU - Repp, Roland

AU - Valerius, Thomas

AU - Fey, Georg H.

PY - 2004/4

Y1 - 2004/4

N2 - Bispecific antibodies offer the possibility of improving effector-cell recruitment for antibody therapy. For this purpose, a recombinant bispecific single-chain Fv antibody (bsscFv), directed against FcγRIII (CD16) and human leucocyte antigen (HLA) class II, was constructed and tested in functional assays. RNA from the hybridomas 3G8 and F3.3, reacting with CD16 and HLA class II, respectively, was used to generate phage display libraries. From these libraries, reactive phages were isolated and the bsscFv was constructed by connecting both single-chain Fv components through a 20 amino acid flexible linker. After expression in SF21 insect cells and chromatographic purification, the bsscFv bound specifically and simultaneously to both antigens. The affinities of the anti-CD16 and the anti-HLA class II scFv components of the bsscFv were 8.6 × 10-8 mol/l and 13.7 × 10-8 mol/l, respectively, which was approximately sevenfold lower than the F(ab) fragments of the parental antibodies. In antibody-dependent cellular cytotoxicity experiments with human mononuclear cells as effectors, the bsscFv-mediated specific lysis of both HLA class II-positive, malignant human B-lymphoid cell lines and primary cells from patients with chronic B-cell lymphocytic leukaemia. Optimal lysis was obtained at bsscFv concentrations of approximately 400 ng/ml, similar to the concentration required for maximum lysis by the corresponding chemically linked bispecific antibody. Thus, this recombinant bsscFv-antibody is an efficient molecule for effector-cell mediated lysis of malignant human B-lymphoid cells.

AB - Bispecific antibodies offer the possibility of improving effector-cell recruitment for antibody therapy. For this purpose, a recombinant bispecific single-chain Fv antibody (bsscFv), directed against FcγRIII (CD16) and human leucocyte antigen (HLA) class II, was constructed and tested in functional assays. RNA from the hybridomas 3G8 and F3.3, reacting with CD16 and HLA class II, respectively, was used to generate phage display libraries. From these libraries, reactive phages were isolated and the bsscFv was constructed by connecting both single-chain Fv components through a 20 amino acid flexible linker. After expression in SF21 insect cells and chromatographic purification, the bsscFv bound specifically and simultaneously to both antigens. The affinities of the anti-CD16 and the anti-HLA class II scFv components of the bsscFv were 8.6 × 10-8 mol/l and 13.7 × 10-8 mol/l, respectively, which was approximately sevenfold lower than the F(ab) fragments of the parental antibodies. In antibody-dependent cellular cytotoxicity experiments with human mononuclear cells as effectors, the bsscFv-mediated specific lysis of both HLA class II-positive, malignant human B-lymphoid cell lines and primary cells from patients with chronic B-cell lymphocytic leukaemia. Optimal lysis was obtained at bsscFv concentrations of approximately 400 ng/ml, similar to the concentration required for maximum lysis by the corresponding chemically linked bispecific antibody. Thus, this recombinant bsscFv-antibody is an efficient molecule for effector-cell mediated lysis of malignant human B-lymphoid cells.

KW - Antibodies

KW - Fc receptors

KW - Major histocompatibility complex

KW - Natural killer cells

KW - Tumour immunity

UR - http://www.scopus.com/inward/record.url?scp=11144356521&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11144356521&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2004.04893.x

DO - 10.1111/j.1365-2141.2004.04893.x

M3 - Article

C2 - 15059139

AN - SCOPUS:11144356521

VL - 125

SP - 167

EP - 179

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 2

ER -